M1 Medulloblastoma: High risk at any age

Robert P. Sanders, Arzu Onar, James M. Boyett, Alberto Broniscer, E. Brannon Morris, Ibrahim Qaddoumi, Gregory T. Armstrong, Frederick A. Boop, Robert A. Sanford, Larry E. Kun, Thomas E. Merchant, Amar Gajjar

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

Background: The prognosis for children with M1 medulloblastoma (positive CSF cytology) has not been well-defin ed. Methods: We retrospectively reviewed the records of 285 newly diagnosed medulloblastoma patients treated between 1984 and 2006. Older children received post-operative craniospinal and tumor bed irradiation; radiotherapy for younger children depended on treatment era and physician/family preference. Results: 55 patients were <3 years old and 230 patients were >3 years old at diagnosis. We detected significant (P < 0.0001) associations between M1 disease and EFS for the entire cohort and for both younger and older patients. Among younger children, M1 patients had lower EFS than M0 (P = 0.0044). Conclusions : Children <3 years old with M1 medulloblastoma fared poorly in our small series. Survival for older children with M1 disease treated with higher-dose CSI was better than that of M2/M3 patients, but still less than optimal; our findings do not support reduction in therapy for either cohort.

Original languageEnglish (US)
Pages (from-to)351-355
Number of pages5
JournalJournal of Neuro-Oncology
Volume90
Issue number3
DOIs
StatePublished - Aug 18 2008

    Fingerprint

Keywords

  • Cytology
  • Infant
  • Medulloblastoma
  • Metastatic
  • Prognosis
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Sanders, R. P., Onar, A., Boyett, J. M., Broniscer, A., Morris, E. B., Qaddoumi, I., Armstrong, G. T., Boop, F. A., Sanford, R. A., Kun, L. E., Merchant, T. E., & Gajjar, A. (2008). M1 Medulloblastoma: High risk at any age. Journal of Neuro-Oncology, 90(3), 351-355. https://doi.org/10.1007/s11060-008-9671-9